CASE [ZIP_CODE] Page 1 Version date: 6/10/21 STUDY NUMBER:  CASE [ADDRESS_1249300] #:  
Protocol Date: 11.04.2019 (Revised 1.16.2020 and 2.4.2020) 
STUDY TITLE:  Comparison of yttrium-90 absorbed doses using PET/CT versus 
PET/MR imaging in patients undergoing selective internal radiation therapy for hepatic 
malignancies  
PRINCIPAL INVESTIGATOR: 
[INVESTIGATOR_892081], M.D.  
Interventional Radiology, Imaging Institute  
Cleveland Clinic 
[ADDRESS_1249301],  
Cleveland, OH [ZIP_CODE] 
 
SPONSOR:  Case Comprehensive Cancer Center 
SUPPORT/FUNDING: Siemens Medical Solutions  
[STUDY_ID_REMOVED]

CASE [ZIP_CODE]   Page 2    Version date: 6/10/21 
 Title: Comparison of yttrium-90 absorbed doses using PET/CT versus PET/MR imaging 
in patients undergoing selective internal radiation therapy for hepatic malignancies   
 
 
Principal Investigator: [INVESTIGATOR_892081], M.D.  
 
 
 
 
 
PRINCIPAL INVESTIGATOR [INVESTIGATOR_12844]: 
 
 
_______________________________________  Date: 2/4/2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CASE [ZIP_CODE]   Page 3    Version date: 6/10/21 
  SUMMARY OF CHANGES 
 
Protocol 
Date  Section  Change  
11/4/2019   Initial IRB approval  reviewed on 11/26/19  
1/16/2020   Revised protocol (version 1) for Initial IRB approval  
2/4/2020   Revised protocol (version 2) for Initial IRB approval  
6/10/21   Revised protocol (version 3) Dosimetry and volumetry results from an 
earlier pi[INVESTIGATOR_284279] 8 cases (IRB#[ADDRESS_1249302] of PET/MR 
Attenuation correction in Y90 dosimetry analysis compared to 
PET/CT ); will be compared to verify their consistency and evaluate the 
validity of using them interchangeably  and will be included in the 
statistical analysis  
   
 
CASE [ZIP_CODE]   Page 4    Version date: 6/10/21 
 PROTOCOL SUMMARY 
 
12 consecutive cases undergoing yttrium-90 radioembolization (Y-90 RE) for hepatic 
malignancies at our institute are consented to participate at this trial. Within 6 hours after 
the procedure, the patients undergo PET/CT and PET/MR imaging (less than 1 hour apart) 
for evaluation of the treatment and software-assisted measurement of yttrium-[ADDRESS_1249303]-Y90 RE dosimetry and 
volumetry results from an earlier pi[INVESTIGATOR_284279] 8 cases (IRB#17-[ADDRESS_1249304] of PET/MR 
Attenuati
on correction in Y90 dosimetry analysis compared to PET/CT ; similar protocol 
design), will be compared to each other to verify their consistency and evaluate the validity 
of using them interchangeably. 
 
 
ABBREVIATIONS  
 
 
 
 CT Computed Tomography  
DSMP  Data and Safety Monitoring Plan  
GCP  Good Clinical Practice  
HIPAA  Health Information Portability and Accountability Act    
ICH International Conference on Harmonization  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
MRI  Magnetic Resonance Imaging  
PET Positron Emission Tomography  
RDC  Reproducibility Coefficient  
RE Radioembolization  
SD Standard Deviation  
SIRT  Selective Internal Radiation Therapy  
SPECT  Single Photon Emission Computed Tomography  
CASE [ZIP_CODE]   Page 5    Version date: 6/10/[ADDRESS_1249305] SELECTION 
4.1 In
clusion Criteria 
4.2  Exclusion Criteria 
4.3 Inclusion of Women and Minorities 
 
5.0 REGISTRATION  
 
6.0 POTENTIAL RISKS 
6.1 Adverse effects 
6.2 Data and Safety Monitoring Plan (DSMP)  
 
7.0 RECORDS TO BE KEPT/REGULATORY CONSIDERATIONS 
7.[ADDRESS_1249306] Data Protection 
7.2.3 Retention of records 
7.2.4 Audits and inspections  
 
REFERENCES  
  
 
 
 
 
 
 
 
 
 
CASE [ZIP_CODE]   Page 6    Version date: 6/10/[ADDRESS_1249307] two decades [1]. Selective internal radiation 
therapy (SIRT) with yttrium (Y)-90 is a well-established modality for palliative 
treatment of primary and metastatic liver malignancies and constitutes delivery of 
radioactive-emitting embolic microspheres through selection of arteries that directly 
feed the tumor. Radioembolization (RE) through this method achieves prolonged 
patient survival with limited systemic adverse effects and acceptable safety profile [2, 
3]. 
1.[ADDRESS_1249308] Y-90 Radioembolization Imaging 
Various imaging modalities including single-photon emission computed tomography 
(SPECT) and positron emission tomography (PET), in combination with computed 
tomography (CT) or magnetic resonance imaging (MRI), are incorporated as part of  
standard patient care after Y-90 RE to evaluate the distribution of radionuclide particles 
within the liver (and elsewhere in the body) and to calculate the radionuclide absorbed 
doses in the tumors, which in turn would permit optimal planning for continuation of 
patientâ€™s care [4]. Accurate tumor Y-[ADDRESS_1249309]-Y-90 RE imaging with PET/CT has been proven to serve as a favorable modality 
for this purpose as it delivers better spatial resolution and higher precision in 
quantifying tumor absorbed doses. These advantages improve Y-90 RE treatment 
planning by [CONTACT_892085]-response and dose-toxicity data [5]. Hence, 
Y-90 PET/CT has become the modality of choice for post-Y-90 RE imaging in many 
centers across the US including our institute. Y-90 PET/MR is another imaging 
modality that may be performed after SIRT with Y-[ADDRESS_1249310] and determination of the liver/tumor contours, compared to Y-90 PET/CT 
imaging [6]. For this reason, post-Y-90 RE PET/MR is frequently performed at our 
institute, encompassing over 200 cases since 2016. Despi[INVESTIGATOR_6831], Y-90 PET/CT still 
provides a better quantification of PET images, due to the better attenuation correction, 
and remains as the gold standard method [6]. This necessitates assessment of the 
validity of dosimetry results acquired by Y-90 PET/MR, in comparison to PET/CT 
imaging.  
1.[ADDRESS_1249311]-Y-90 RE dosimetry results between PET/CT and 
PET/MR imaging, the current investigators observed significant inconsistencies 
CASE [ZIP_CODE]   Page 7    Version date: 6/10/21 
 between  the two modalities; in other words, tumor absorbed doses were on average 
36% (SD = 43%) lower in PET/MR-based calculations than in PET/CT [7]. This 
resulted in PET/MR software upgrades which predominantly included a few 
improvements in the attenuation correction as well as the respi[INVESTIGATOR_892082]. I
n order to validate these PET/MR-based dosimetry upgrades, this protocol 
was 
designed including another pi[INVESTIGATOR_9416] 8 cases, to compare Y-90 dosimetry data 
between PET/CT and PET/MR. Given the promising results of the second pi[INVESTIGATOR_4251] 
(IRB#17-[ADDRESS_1249312] of PET/MR Attenuation correction in Y90 dosimetry analysis 
compar
ed to PET/CT), the investigators are proposing this study (with similar design) 
to extend their research on more cases. 
 
2.[ADDRESS_1249313]-Y-90 RE absorbed doses (Gy) in the liver tumor 
tissues based on PET/CT versus PET/MR imaging. This objective would permit the 
comparison of Y-90 tumor absorbed doses, acquired from PET/MR, with the current 
standard 
of care PET/CT imaging to verify the data consistency and to validate its 
appli
cation for the prediction of tumor response to treatment. The endpoint for this 
objective would be the measurement of the reproducibility coefficient (RDC) between 
the two imaging modalities for post-Y-90 RE absorbed doses (Gy) in the liver tumor 
tissues (please see the Study Design for further details). 
2.[ADDRESS_1249314]-Y-90 RE absorbed doses (Gy) in the background 
liver tissues (surrounding tumors), based on PET/CT versus PET/MR imaging. This 
objective would permit the comparison of Y-90 background liver absorbed doses, 
acquired from PET/MR,  with the current standard of care PET/CT imaging to verify the 
data consistency and to validate its application for the prediction of dose toxicity. The 
endpoint
 for this objective would be the measurement of the RDC between the two 
imaging modalities for post-Y-90 RE absorbed doses (Gy) in the background liver 
tissues (please see the Study Design for further details). 
 
3.0 S
TUDY DESIGN 
3.1 Number of Subjects 
Upon IRB approval and patientâ€™s informed consent, 12 new consecutive cases will be 
enrolled in the study. The sample size calculation (n = 12) is based on the fact that the 
CASE [ZIP_CODE]   Page 8    Version date: 6/10/21 
 RDC should be < 5% for clinical use.  The following table summarizes the  estimated  
upper 95% confidence bound for the RDC as a function of the unknown RDC.  Based 
on this table  and our expectation that our new technique will have an excellent 
reproducib ility with PET , a sample size of 12 will provide sufficient precision  to 
determine if the RDC with our new technique is near 5%. 
Estimated Upper 95% Confidence Bound  for RDC  
 Magnitude of RDC  
# Cases RDC=2%  RDC=3%  RDC=4%  RDC=5%  
10 3.2 4.8 6.4 8.0 
12 3.0 4.5 6.1 7.6 
15 2.9 4.3 5.7 7.2 
 
 
3.2 Study Protocol 
 
The study protocol is outlined in the diagram below. Upon the patientâ€™s informed 
consent and eligibility approval (according to the inclusion/exclusion criteria below) 
for participation in the trial, they undergo PET/CT (standard imaging) and PET/MR 
(additional imaging), within [ADDRESS_1249315], based on the availability of the imaging device, and less than 1 hour 
apart. This limited time threshold allows to ignore the trivial amounts of Î²âˆ’ decay in 
radionuclide emission that happens after trans-arterial delivery of Y-90 microspheres 
into the liver, with regards to its half-life of ~64 hours. Upon acquirement and 
construction of PET/CT and PET/MR images, a software (MIM SurePlan LiverY90) 
would be utilized for semi-automatic determination of the liver/tumor contours and 
calculation of the Y-90 absorbed doses (Gy) in the regions of interest (including within 
tumor and background liver outlines) using the Local Deposition Method.  
 
Dosimetry/volumetry data from the two modalities from these cases, in addition to the 
results from the pi[INVESTIGATOR_389164] (IRB#17-[ADDRESS_1249316] of PET/MR Attenuation correction in 
Y90 dosimetry analysis compared to PET/CT ; similar protocol design), w ill be 
compared using the Bland Altman method to assess the pattern of differences between 
dosimetr
y values and to measure the reproducibility of the methods [8]. The RDC is 
the minimum difference between the two measurements that can be considered a true 
difference, with 95% confidence.  It will be calculated as 2.[ADDRESS_1249317] 
SD (wS
D), where wSD is the square root of the mean variance across the N subjects, 
and the variance for each subject is calculated from the ir two dosimetry values [9,10] . 
In addition, the reproducibility coefficient will also be expressed as a percentage of a 
subje
ctâ€™s PET/CT value of dose, using the within-subject coefficient of variation 
CASE [ZIP_CODE]   Page 9    Version date: 6/10/21 
 (wCV) instead of wSD . An upper 95% confidence bound for the RDC will be 
constructed using a chi square statistic as the pi[INVESTIGATOR_325618], as follows: 
2.77 Ã— âˆšð‘ Ã—  %ð‘¤ð¶ ð‘‰2/ðœ’ð‘€,ð›¼2, where ðœ’ð‘€,ð›¼2 is the ð›¼th percentile of the chi square 
distribution with N degrees of freedom. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.[ADDRESS_1249318] Participation 
The study involves one-time PET/MR imaging in addition to the standard PET/CT 
imaging, both performed on the same day of the treatment procedure (Y-90 RE). Upon 
completion of the imaging procedures, the patientâ€™s involvement in the study would be 
completed. The researchers, however, will need to access the patientâ€™s medical records 
to record basic medical information including the patient demographics, diagnosis, and 
treatment and to analyze the imaging data and dosimetry. 
 
4.[ADDRESS_1249319] SELECTION 
4.1 Inclusion Criteria 
A) The patient has a liver malignancy and is scheduled for SIRT with Y-90; AND 
B) The 
patient is an adult (18 years or above), self-competent, and able to provide 
informed c
onsent to participate in the study 
4.2 E
xclusion Criteria Patient's consent & 
eligibility approval
Y-90 RE
PET/CT followed by 
[CONTACT_10052]/MR (within 1h)
Image analysis & 
Y-90 dosimetryPET/MR followed by 
[CONTACT_10052]/CT (within 1h)
CASE [ZIP_CODE]   Page 10    Version date: 6/10/21 
 A) The patient loses competence, has a condition that questions their ability to provide 
informed consent independently (e.g. cannot communicate in English), or withdraws 
consent to participate within any time in the study period; OR 
B) The patient is not eligible to undergo MRI due to the presence of metal devices or 
implants in their body; OR 
C) Both imaging modalities cannot take place within 6 hours after Y-90 RE; OR 
D) Both imaging modalities cannot take place within [ADDRESS_1249320] been consented are to be registered in the OnCoreâ„¢ Database. For 
those subjects who are consented, but not enrolled, the reason for exclusion must be 
recorded. 
 
6.0 POTENTIAL RISKS 
6.1 Adverse effects 
 
The additional PET/MR imaging in this study does not involve any extra radiation to 
the patient, besides what one would receive as part of the standard protocol during Y-
90 RE and PET/CT imaging. There are no known biological risks associated with 
PET/MRI.  A PET/MRI procedure may cause possible anxiety in some individuals, due 
to t
he confined space of the testing area resulting in feelings of claustrophobia and the 
loud banging made by [CONTACT_101488]. The patients retain the right to withdraw from 
participating in the study in such conditions. 
Since the MRI is a powerful magnet, patients cannot be scanned if they have certain 
metal devices in their body.  There is also a risk of injury if metal is brought into the 
imaging room, which may be pulled into the magnet.  Patients will be asked to remove 
any magnetic objects from their clothes and body in order to prevent any injuries.  A 
safety zone is established around the MR scanner to prevent objects containing iron 
from coming into contact [CONTACT_521627]. 
6.2 Data and Safety Monitoring Plan (DSMP) 
This protocol wil
l adhere to the policies of the Case Comprehensive Cancer Center 
Data and Safety Monitoring Plan in accordance with NCI guidelines.  
CASE [ZIP_CODE]   Page 11    Version date: 6/10/21 
  
7.0 RECORDS TO BE KEPT/REGULATORY CONSIDERATIONS 
7.1 Data Reporting  
The OnCoreâ„¢ Database would be utilized, as required by [CONTACT_482595], in order to provide data collection for both accrual entry and trial 
data management. OnCoreâ„¢ is a Clinical Trials Management System housed on 
secure servers maintained at Case Western Reserve University. Access to data 
through OnCoreâ„¢ is restricted by [CONTACT_113298]. Once logged 
into the OnCoreâ„¢ system with a user ID and password. OnCoreâ„¢ defines roles 
for each user which limits access to appropriate data. User information and 
password can be obtained by [CONTACT_165327]â„¢ Administrator at OnCore-
[EMAIL_1272]. 
OnCoreâ„¢ is designed with the capability for study setup, activation, tracking, 
reporting, data monitoring and review, and eligibility verification. This study 
would
 utilize electronic Case Report Form completion in the OnCoreâ„¢ database. 
A calendar of events and required forms are available in OnCoreâ„¢. 
7.2 Regulatory Considerations 
 
The study would be conducted in compliance with the IRB-approved protocol, HIPA A 
and ICH guidelines, as well as all applicable federal (including 21 CFR parts 56 & 50), 
state a
nd local regulations. 
7.2.[ADDRESS_1249321]â€™s financial responsibility. Subjects would 
also
 be notified that they are free to discontinue from the study at any time. The subject 
would be given the opportunity to ask questions and be allowed time to consider the 
information provide
d. 
The original, signed written Informed Consent Form would be kept with the Research 
Cha
rt in conformance with the institutionâ€™s standard operating procedures. A copy of 
the signed written Informed Consent Form would be given to the subject. Additionally, 
doc
umentation of the consenting process would be located in the research chart. 
7.2.[ADDRESS_1249322] 
(HIPAA), all study subjects would sign an authorization to release medical information 
to the sponsor and/or allow the sponsor, a regulatory authority, or Institutional Review 
CASE [ZIP_CODE]   Page 12    Version date: 6/10/[ADDRESS_1249323]â€™s medical information that includes all hospi[INVESTIGATOR_201733], including subjectsâ€™ medical history.  
7.2.3 Retention of records 
The
 Principal Investigator [INVESTIGATOR_892083], national and international regulations. No records 
would be destroyed until the Principal Investigator [INVESTIGATOR_113282].  
7.2.4 Audits and inspections  
Author
ized representatives of the sponsor, a regulatory authority, an Independent 
Ethics Committee (IEC) or an Institutional Review Board (IRB) may visit the site to 
perform audits or inspections, including source data verification. The purpose of an 
audit or inspection is to systematically and independently examine all study-related 
activities and documents to determine whether these activities were conducted, and 
data were recorded, analysed, and accurately reported according to the protocol, Good 
Clinical Practice (GCP), guidelines of the International Conference on Harmonization 
(ICH), and any applicable regulatory requirements. For multi-center studies, 
participating sites must inform the sponsor-investigator of pending audits.  
 
REFERENCES 
1. American Cancer Society. Global cancer Facts and figures. 3rd edition. Atlanta: 
Ame
rican Cancer Society; 2015. 
2. Bozkurt MF, Salanci BV, UÄŸur Ã– . Intra-arterial radionuclide therapi[INVESTIGATOR_892084]. Semin Nucl Med 2016; 46(4):324-39. 
3. Ibrahim SM , Lewandowski RJ , Sato KT , Gates VL , Kulik L , Mulcahy MF, Ryu 
RK, Omary RA , Salem R . Radioembolization for the treatment of unresectable 
hepatocellular carcinoma: a clinical review. World J Gastroenterol  2008; 14(11): 
1664 -9. 
4. Camacho JC, Moncayo V, Kokabi N, Reavey HE, Galt JR, Yamada K, Kies DD, 
Williams RS, Kim HS, Schuster DM. (90)Y Radioembolization: Multimodality 
ima
ging pattern approach with angiographic correlation for optimized target 
therapy delivery. Radiographics 2015; 35(5): 1602-18. 
5. Tafti BA, Padia SA. Dosimetry of Y -[ADDRESS_1249324] and 
Y-90 PET. Semi n Nucl Med 2019; 49: 211 -217. 
6. KneÅ¡aurek K, Tuli A, Kim E, Heiba S, Kostakoglu L. Comparison of PET/CT and 
P
ET/MR imaging and dosimetry of yttrium-90 (90Y) in patients with unresectable 
hepatic tumors who have received intra-arterial radioembolization therapy with 
90Y microspheres. EJNMMI Phys 2018; 5 (1):23. 
CASE [ZIP_CODE]   Page 13    Version date: 6/10/21 
 7. Gurajala RK, Hunter SA, DiFilippo FP, Karuppasamy K, Shrikanthan S, Coppa 
CP, Gadodia G, Levitin A. PET/CT versus PET/MR: Quantitative accuracy in Y -
90 dosimetry analysis. 104th Scientific Assembly  and Annual Meeting of 
Radiologic Society of North America (RSNA). Chicago (IL), [LOCATION_003] (25 -30 Nov 
2018).  
8. Bland JM, Altman DG. Statistical method for assessing agreement between two 
methods of clinical measurement. Lancet 1986; 327: [ADDRESS_1249325]  Methods. I: Guide for the determination and reproducibility for a 
standard test method. London: British Standards Institution; 1976. p. 54 -97. 
10. Obuchowski, NA; Reeves, AP; Huang, EP;  Wang, XF; Buckler, AJ; Kim, HJ; 
Ba
rnhart, HX; Jackson, EF; Giger, ML; Pennello, G; Toledano, AY; Kalpathy-
Cramer, J; Apanasovich, TV; Kinahan, PE; Myers, KJ; Goldgof, DB; Barboriak, 
DP; Gillies, RJ; Schwartz, LH; Sullivan, DC. Quantitative imaging biomarkers: A 
review of statistical methods for computer algorithm comparisons.  Stat. Methods 
Me
d. Res . 2015; 24:68-106. 